COMP <GO>
CYTK vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Cytokinetics Incorporated (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CYTK 3
— ABBV 11
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: CYTK
LAST: $62.99 (-0.51%) • MKT CAP: $8.80B
options-implied-move
6.50%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYTK VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYTK | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.08% | 3.47% | -9.55 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 8.60% | +171.40 | CYTK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.33 | -4.88 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.50% | 7.40% | -0.90 | CYTK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.0 | 72.8 | -26.79 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.15 | -0.28 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 113.1x | -82.10 | CYTK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.80B | $513.86B | -$505.06B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYTK REV | ABBV REV | CYTK GROSS % | ABBV GROSS % | CYTK FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $88.0M | $61.16B | 44.0% | 70.2% | -$534.8M | $17.82B |
| FY 2024 | $18.5M | $56.33B | 44.0% | 70.0% | -$399.8M | $17.83B |
| FY 2023 | $7.5M | $54.32B | 44.0% | 44.0% | -$414.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYTK // BETA 0.87
ABBV // BETA 1.15